Access Pharmaceuticals Receives $700,000 Initial Purchase Order

ACCESS PHARMACEUTICALS, INC. (ACCP) announced today it has received its first commercial order for MuGard from BioScrip BIOS. BioScrip's initial purchase order of MuGard, totaling over $700,000, will provide adequate inventory for its various distribution channels to support the Company's first phase of its product launch for MuGard. Access Pharmaceuticals has inventory on hand and will begin shipping product to BioScrip immediately. MuGard is an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiation and/or chemotherapy.